kastlem

ASCO: Whose Presentations Look the Most Promising?

Erbitux and Vectibix Grade 3 & 4 acneform rashes, and hypomagnemia are significant in their safety profiles. I feel Nimotuzumab (95% humanized monoclonal EGFR targeting anti-body which trialed against these two) is interesting as these side effects were reduced to <1%. YMI may be small but with a remarkable safety profile in comparision, it could give the big pharma a run for its money. We shall see. Nimo also is best used in patients with normal KRAS gene. It is worth noting radiotherapy increases EGFR expression.